VCYT Veracyte Inc
Price (delayed)
$30.56
Market cap
$2.38B
P/E Ratio
95.5
Dividend/share
N/A
EPS
$0.32
Enterprise value
$2.19B
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other
Highlights
Veracyte's net income has surged by 132% YoY
The EPS has surged by 131% year-on-year
The debt has soared by 158% from the previous quarter
The company's quick ratio fell by 7% QoQ
Key stats
What are the main financial stats of VCYT
Market
Valuations
Earnings
Shares outstanding
77.94M
Market cap
$2.38B
Enterprise value
$2.19B
Price to earnings (P/E)
95.5
Price to book (P/B)
2.01
Price to sales (P/S)
5.24
EV/EBIT
85.15
EV/EBITDA
40.48
EV/Sales
4.92
Revenue
$445.76M
Gross profit
$298.15M
Operating income
$16.14M
Net income
$24.14M
EBIT
$25.74M
EBITDA
$54.16M
Free cash flow
$63.81M
Per share
Balance sheet
Liquidity
EPS
$0.32
EPS diluted
$0.31
Free cash flow per share
$0.83
Book value per share
$15.17
Revenue per share
$5.83
TBVPS
$5.91
Total assets
$1.3B
Total liabilities
$124.07M
Debt
$50.74M
Equity
$1.18B
Working capital
$293.63M
Debt to equity
0.04
Current ratio
4.73
Quick ratio
4.29
Net debt/EBITDA
-3.51
Margins
Efficiency
Dividend
EBITDA margin
12.1%
Gross margin
66.9%
Net margin
5.4%
Operating margin
3.6%
Return on assets
1.9%
Return on equity
2.1%
Return on invested capital
24.6%
Return on capital employed
2.1%
Return on sales
5.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VCYT stock price
How has the Veracyte stock price performed over time
Intraday
-1.29%
1 week
-6%
1 month
-22.81%
1 year
38.47%
YTD
-22.83%
QTD
-22.83%
Financial performance
How have Veracyte's revenue and profit performed over time
Revenue
$445.76M
Gross profit
$298.15M
Operating income
$16.14M
Net income
$24.14M
Gross margin
66.9%
Net margin
5.4%
The operating income has soared by 169% from the previous quarter and by 119% YoY
The operating margin has soared by 165% from the previous quarter and by 115% YoY
Veracyte's net income has surged by 132% YoY
The net margin has soared by 126% YoY
Growth
What is Veracyte's growth rate over time
Valuation
What is Veracyte stock price valuation
P/E
95.5
P/B
2.01
P/S
5.24
EV/EBIT
85.15
EV/EBITDA
40.48
EV/Sales
4.92
The EPS has surged by 131% year-on-year
The P/B is 24% below the 5-year quarterly average of 2.7 but 7% above the last 4 quarters average of 1.9
The equity has grown by 13% YoY
The P/S is 47% below the 5-year quarterly average of 10.0
Veracyte's revenue has increased by 23% YoY and by 4.8% QoQ
Efficiency
How efficient is Veracyte business performance
The company's return on equity has surged by 130% YoY
The ROA has soared by 129% YoY
The return on sales has surged by 127% year-on-year
VCYT's return on invested capital has surged by 120% year-on-year
Dividends
What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VCYT.
Financial health
How did Veracyte financials performed over time
The total liabilities has soared by 75% YoY and by 25% from the previous quarter
Veracyte's total assets has increased by 17% YoY
The debt is 96% less than the equity
The debt has soared by 158% from the previous quarter
VCYT's debt to equity has surged by 100% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.